查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1864671

分子诊断自动化市场按产品类型、最终用户、技术、自动化程度和应用划分－2025-2032年全球预测

Automation in the Molecular Diagnostics Market by Product Type, End User, Technology, Automation Level, Application - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，分子诊断自动化市场规模将达到 454.2 亿美元，复合年增长率为 16.33%。

关键市场统计数据
基准年 2024 135.4亿美元
预计年份：2025年 157.8亿美元
预测年份 2032 454.2亿美元
复合年增长率 (%) 16.33%

分子诊断自动化如何重塑临床和研究环境中的检查室工作流程、品质预期和策略重点

对于分子诊断检查室，自动化不再是渐进式改进，而是影响临床吞吐量、资料完整性和营运韧性的策略要务。机器人技术、整合检体处理和云端数据分析的进步正与不断变化的临床需求相融合，共同创造出一个检查室能够减少人工操作时间、标准化通讯协定并提供更快、更可重复结果的环境。因此，自动化不仅影响日常运营，也影响资本投资规划、人才培育和供应商选择。

分子诊断领域正经历着由整合自动化、互通软体以及不断变化的临床和营运需求所驱动的重大变革。

分子诊断领域正经历变革性的转变，这主要得益于技术的成熟、工作流程的整合以及不断变化的临床需求。定序平台和高通量PCR系统与微阵列解决方案以及从样本到结果的先进数据分析工具相辅相成，使检查室能够扩展检测项目并缩短週转时间。同时，软体编配和云端基础的分析技术也使得复杂的多仪器工作流程的管理更加透明和审核。

评估不断变化的美国关税政策对诊断设备製造商和检查室的采购、供应链韧性和策略采购决策的影响

美国近期关税政策的变化和贸易政策的调整正在影响分子诊断设备、耗材和软体的采购和供应动态。实验室和诊断设备供应商面临着不断变化的成本结构，这影响着他们的采购选择、库存策略和合约谈判。随着关税改变进口零件和成品的相对经济效益，各机构正在重新评估其供应商布局，并考虑其他製造地和本地库存策略，以降低风险并维持医疗服务的连续性。

全面的細項分析重点阐述了产品类型、最终用户、技术、自动化等级和应用如何驱动产品采用、价值和供应商策略。

細項分析揭示了产品类型、最终用户、技术、自动化程度和应用领域如何影响诊断生态系统的采用模式和价值实现。根据产品类型，产品范围涵盖耗材和试剂（例如，微阵列晶片、次世代定序样品製备盒和PCR试剂盒）、仪器（例如，微阵列系统、NGS仪器和PCR仪器），以及软体和服务（包括数据分析平台、整合服务和管理服务）。这些类别相互影响：仪器的普及推动了对耗材的持续需求，而软体和服务则实现了高价值的应用场景和营运扩充性。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 将高通量自动化技术整合到次世代定序流程中，可以缩短週转时间。
  • 在分散式诊断实验室中实施用于多重PCR检测的机器人样本製备平台
  • 实施人工智慧驱动的数据分析流程，用于即时解读分子诊断结果
  • 开发用于偏远地区照护现场核酸检测的模组化实验室晶片设备
  • 标准化自动化液体处理通讯协定，以提高多站点分子检测网路的可重复性
  • 扩展的封闭式自动化系统结合了样本提取和qPCR技术，以最大限度地降低污染风险和操作人员误差。

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 按产品类型分類的分子诊断自动化市场

  • 耗材和试剂
    • 微阵列晶片
    • 次世代定序样品製备盒
    • PCR试剂盒
  • 装置
    • 微阵列系统
    • 次世代定序设备
    • PCR设备
  • 软体和服务
    • 数据分析软体
    • 整合服务
    • 託管服务

9. 按最终用户分類的分子诊断自动化市场

  • 临床实验室
  • 医院实验室
  • 製药和生物技术公司
  • 参考实验室
  • 研究实验室

第十章 依技术分類的分子诊断自动化市场

  • 微阵列
  • 次世代定序（NGS）
  • PCR

第十一章 分子诊断自动化市场（依自动化程度划分）

  • 全自动系统
  • 半自动系统
  • 无人值守自动化

第十二章：按应用分類的分子诊断自动化市场

  • 心血管疾病
  • 基因检测
  • 感染疾病
  • 肿瘤学
  • 女性健康

第十三章 各地区分子诊断自动化市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 分子诊断自动化市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国分子诊断自动化市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • F. Hoffmann-La Roche Ltd
    • Thermo Fisher Scientific Inc.
    • Danaher Corporation
    • Abbott Laboratories
    • QIAGEN NV
    • bioMerieux SA
    • Bio-Rad Laboratories, Inc.
    • Siemens Healthineers AG
    • PerkinElmer, Inc.
    • Agilent Technologies, Inc.
Product Code: MRR-2D1F5C65740B

The Automation in the Molecular Diagnostics Market is projected to grow by USD 45.42 billion at a CAGR of 16.33% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 13.54 billion
Estimated Year [2025] USD 15.78 billion
Forecast Year [2032] USD 45.42 billion
CAGR (%) 16.33%

How automation in molecular diagnostics is redefining laboratory workflows, quality expectations, and strategic priorities across clinical and research environments

Automation is no longer an incremental improvement for molecular diagnostics laboratories; it has become a strategic imperative that affects clinical throughput, data integrity, and operational resilience. Advances in robotics, integrated sample processing, and cloud-enabled data analysis are converging with evolving clinical needs to create a landscape where laboratories can reduce hands-on time, standardize protocols, and deliver faster, more reproducible results. As a result, automation influences not only day-to-day operations but also capital planning, workforce development, and vendor selection.

Moreover, the drivers of automation extend beyond simple efficiency gains. Regulatory expectations for traceability and quality, the need to scale testing during infectious disease surges, and the demand for complex genomic assays in oncology and hereditary disease testing all push laboratories toward higher degrees of automation. In turn, suppliers respond with modular architectures, scalable software platforms, and expanded service models. Consequently, stakeholders must view automation as a systems-level change that intersects with clinical strategy, IT infrastructure, and supply chain management.

Key transformative shifts in the molecular diagnostics landscape driven by integrated automation, interoperable software, and evolving clinical and operational demands

The molecular diagnostics landscape is experiencing transformative shifts driven by technology maturation, workflow integration, and changing clinical demand. Sequencing platforms and high-throughput PCR systems now coexist with sample-to-answer microarray solutions and sophisticated data analysis tools, enabling laboratories to broaden their test menus and reduce turnaround times. At the same time, software-enabled orchestration and cloud-based analytics are making it feasible to manage complex multi-instrument workflows with greater transparency and auditability.

Transitioning from fragmented instrument fleets to integrated automation ecosystems also alters procurement approaches and vendor relationships. Suppliers that deliver interoperability, validated workflows, and long-term service agreements gain strategic advantage. Meanwhile, laboratories prioritize solutions that reduce manual interventions, limit contamination risk, and enable remote monitoring. Taken together, these shifts are driving consolidation of point technologies into end-to-end solutions, aligning technical innovation with clinical and operational imperatives.

Assessing how evolving United States tariff policies influence procurement, supply chain resilience, and strategic sourcing decisions across diagnostics manufacturers and laboratories

Recent tariff developments and trade policy changes in the United States have influenced the procurement and supply dynamics for molecular diagnostics equipment, consumables, and software. Laboratories and diagnostic suppliers face an evolving cost structure that affects sourcing choices, inventory strategies, and contractual negotiations. As tariffs alter the relative economics of imported components and finished products, organizations reassess supplier footprints and consider alternative manufacturing locations or local stocking strategies to mitigate exposure and preserve continuity of care.

In response to these trade-induced pressures, industry participants increasingly emphasize supplier diversification and nearshoring. Procurement teams work to redesign contracts with clearer clauses for tariffs, duties, and lead-time variability while supply chain teams collaborate with logistics partners to maintain buffer inventories without sacrificing cold-chain integrity. Concurrently, manufacturers respond by optimizing bill-of-materials, qualifying alternate suppliers, and in some cases accelerating regional manufacturing investments. The cumulative effect reshapes commercial conversations around pricing transparency, service commitments, and risk-sharing arrangements, prompting both buyers and sellers to adopt more resilient, collaborative procurement models.

Comprehensive segmentation insights highlighting how product categories, end users, technologies, automation levels, and applications determine adoption, value, and vendor strategies

Segmentation analysis reveals how product type, end user, technology, automation level, and application areas shape adoption patterns and value realization across the diagnostics ecosystem. Based on product type, offerings range from consumables and reagents-encompassing microarray chips, next-generation sequencing library preparation kits, and PCR kits-to instruments such as microarray systems, NGS instruments, and PCR instruments, as well as software and services that include data analysis platforms, integration services, and managed services. These categories interact: instrument adoption often drives recurring consumable demand while software and services facilitate higher-value use cases and operational scalability.

Based on end user, adoption trajectories diverge among clinical laboratories, hospital laboratories, pharmaceutical and biotechnology companies, reference laboratories, and research laboratories. Each segment prioritizes different performance attributes: clinical laboratories emphasize throughput and regulatory compliance, hospital labs focus on rapid turnaround for patient care, pharmaceutical and biotech customers seek scalability for drug development workflows, reference laboratories value consolidation and automation economies, and research labs often prioritize flexibility and cutting-edge capabilities. Based on technology, choices center on microarrays, NGS, and PCR, with each modality offering distinct trade-offs in sensitivity, resolution, and workflow complexity. Automation level further stratifies the landscape into fully automated systems, semi-automated systems, and walkaway automation, each balancing capital intensity against labor savings. Finally, application areas such as cardiovascular disease screening, genetic testing, infectious disease diagnostics, oncology, and women's health create specialized requirements for sample throughput, assay validation, and data interpretation. By synthesizing these segmentation axes, stakeholders can align product roadmaps, service offerings, and commercialization strategies with the differentiated needs of laboratory segments and clinical applications.

Regional insights illustrating how distinct clinical infrastructure, procurement practices, and regulatory environments in the Americas, EMEA, and Asia-Pacific shape automation adoption and commercialization

Regional dynamics shape technology adoption, reimbursement pathways, and supply chain priorities across the molecular diagnostics landscape. In the Americas, advanced laboratory networks and consolidated reference labs drive demand for high-throughput automation and integrated data platforms, while investments in infrastructure and a focus on scale encourage vendor partnerships that emphasize service and local support. In contrast, the Europe, Middle East & Africa region presents a heterogeneous picture: many markets pursue harmonized regulatory frameworks and centralized genomic initiatives, yet infrastructure variability and fragmented procurement practices require flexible, modular solutions that can operate across diverse clinical contexts.

Meanwhile, Asia-Pacific demonstrates rapid adoption of automation in both centralized and decentralized testing environments, supported by strong domestic manufacturing capabilities in several markets and a growing emphasis on genomic medicine. These regional differences affect vendor go-to-market strategies, with successful suppliers tailoring distribution models, validation packages, and training services to local regulatory regimes and laboratory maturity levels. Consequently, regional insight must inform any commercialization plan, supply chain design, and customer engagement approach to ensure compatibility with local clinical workflows and procurement expectations.

Key company strategies reveal how platform integration, modular architectures, service excellence, and regulatory expertise differentiate competitive positioning and vendor selection

Leading companies in the molecular diagnostics automation space follow differentiated strategies that reflect technological strengths, service models, and route-to-market choices. Some vendors prioritize platform-based approaches that integrate instruments, consumables, and software to lock in long-term recurring revenue and ensure validated end-to-end workflows. Others compete on modularity and open-architecture systems that appeal to customers seeking flexibility and the ability to mix and match instruments from multiple suppliers. Across both approaches, investments in connectivity, remote monitoring, and lifecycle services increasingly determine competitive positioning.

Moreover, successful organizations emphasize regulatory expertise and global service footprints to reduce adoption friction for customers operating across jurisdictions. Partnerships with laboratory networks and strategic alliances with software providers accelerate time-to-implementation and broaden addressable use cases. Additionally, several companies leverage scale in manufacturing and distribution to improve supply reliability and absorb logistical challenges. For buyers, this translates into evaluating suppliers not only on instrument performance but also on their ability to deliver validated workflows, dependable service, and long-term roadmap alignment that supports evolving clinical needs.

Actionable recommendations for laboratory executives and vendors to align automation investments with clinical priorities, supply chain resilience, workforce transformation, and interoperability goals

Industry leaders should adopt a proactive posture to capture the benefits of automation while managing risk across clinical, operational, and commercial domains. First, align automation investments with clinical priorities by piloting solutions that address high-volume, high-impact assays and that demonstrate reproducible gains in turnaround time and error reduction. Simultaneously, develop workforce transition plans that reskill laboratory staff for automation oversight, data interpretation, and instrument maintenance to maximize return on technology investments.

Second, strengthen supply chain resilience through multi-source sourcing strategies, regionally diversified inventory, and contractual terms that account for tariff and logistics variability. Third, prioritize interoperability and data standards when procuring instruments and software to facilitate integration with laboratory information systems and to enable scalable analytics. Fourth, negotiate service-level agreements that include remote diagnostics, preventative maintenance, and clear escalation pathways to minimize downtime. Finally, pursue strategic partnerships with vendors that offer validated workflows and training programs, thereby reducing deployment risk and accelerating clinical adoption. By combining these tactical moves into a cohesive automation roadmap, organizations can sustain operational continuity while unlocking higher-value molecular diagnostics capabilities.

A rigorous mixed-methods research approach combining stakeholder interviews, technical validation, secondary literature, and scenario analysis to produce reliable, application-oriented insights

The research methodology synthesizes primary and secondary evidence, qualitative interviews, and technical validation to ensure robust, actionable insights. Primary research included structured interviews with laboratory directors, procurement leaders, and senior technical staff across clinical, hospital, reference, pharmaceutical, and research laboratory settings to capture firsthand perspectives on automation drivers, barriers, and implementation outcomes. These interviews informed deeper analysis of workflow requirements, staffing implications, and technology selection criteria.

Secondary research drew on peer-reviewed literature, regulatory guidance, company technical documentation, and supply chain data to validate product capabilities, integration standards, and service models. Integrative analysis used cross-validation techniques to reconcile stakeholder testimony with documented performance characteristics and published case studies. In addition, scenario analysis examined procurement and tariff sensitivities, while technology maturity assessments evaluated readiness levels for different automation modalities. Throughout, quality control processes ensured transparency in data sources and reproducibility of conclusions, enabling decision-makers to apply findings with confidence in operational planning and vendor selection.

Concluding synthesis emphasizing how strategic automation adoption transforms diagnostic capability, operational resilience, and clinical value delivery across laboratory environments

Automation in molecular diagnostics has moved from a niche efficiency play to a central element of laboratory strategy, affecting how organizations deliver diagnostics, manage risk, and compete in value-based healthcare settings. Integrated automation reduces manual variability, improves throughput, and enables complex genomic workflows that were previously constrained by labor and instrumentation fragmentation. As a result, laboratories that adopt automation strategically gain advantages in turnaround time, reproducibility, and the ability to scale novel assays into routine practice.

Looking ahead, the interplay between technology providers, laboratories, and regulatory frameworks will determine the pace and pattern of adoption. Organizations that prioritize interoperability, supply chain resilience, and workforce readiness will navigate disruptions more effectively and capitalize on opportunities to extend services and enter new clinical domains. In sum, automation represents both a technological enabler and a business lever; when applied thoughtfully, it transforms laboratory capability and supports higher-quality patient care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of high-throughput automation systems in next-generation sequencing workflows to reduce turnaround times
  • 5.2. Adoption of robotic sample preparation platforms for multiplex PCR assays in decentralized diagnostic labs
  • 5.3. Implementation of AI-driven data analysis pipelines for real-time interpretation of molecular diagnostic results
  • 5.4. Development of modular lab-on-a-chip devices enabling automated point-of-care nucleic acid testing in remote settings
  • 5.5. Standardization of automated liquid handling protocols to enhance reproducibility across multi-site molecular testing networks
  • 5.6. Expansion of closed system automation combining sample extraction and qPCR to minimize contamination risk and operator error

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Automation in the Molecular Diagnostics Market, by Product Type

  • 8.1. Consumables & Reagents
    • 8.1.1. Microarray Chips
    • 8.1.2. Ngs Library Prep Kits
    • 8.1.3. Pcr Kits
  • 8.2. Instruments
    • 8.2.1. Microarray Systems
    • 8.2.2. Ngs Instruments
    • 8.2.3. Pcr Instruments
  • 8.3. Software & Services
    • 8.3.1. Data Analysis Software
    • 8.3.2. Integration Services
    • 8.3.3. Managed Services

9. Automation in the Molecular Diagnostics Market, by End User

  • 9.1. Clinical Laboratories
  • 9.2. Hospital Laboratories
  • 9.3. Pharmaceutical & Biotechnology Companies
  • 9.4. Reference Laboratories
  • 9.5. Research Laboratories

10. Automation in the Molecular Diagnostics Market, by Technology

  • 10.1. Microarrays
  • 10.2. Ngs
  • 10.3. Pcr

11. Automation in the Molecular Diagnostics Market, by Automation Level

  • 11.1. Fully Automated Systems
  • 11.2. Semi-Automated Systems
  • 11.3. Walkaway Automation

12. Automation in the Molecular Diagnostics Market, by Application

  • 12.1. Cardiovascular Diseases
  • 12.2. Genetic Testing
  • 12.3. Infectious Disease
  • 12.4. Oncology
  • 12.5. Women's Health

13. Automation in the Molecular Diagnostics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Automation in the Molecular Diagnostics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Automation in the Molecular Diagnostics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. F. Hoffmann-La Roche Ltd
    • 16.3.2. Thermo Fisher Scientific Inc.
    • 16.3.3. Danaher Corporation
    • 16.3.4. Abbott Laboratories
    • 16.3.5. QIAGEN N.V.
    • 16.3.6. bioMerieux SA
    • 16.3.7. Bio-Rad Laboratories, Inc.
    • 16.3.8. Siemens Healthineers AG
    • 16.3.9. PerkinElmer, Inc.
    • 16.3.10. Agilent Technologies, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION LEVEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION LEVEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROARRAY CHIPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROARRAY CHIPS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROARRAY CHIPS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROARRAY CHIPS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROARRAY CHIPS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROARRAY CHIPS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY NGS LIBRARY PREP KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY NGS LIBRARY PREP KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY NGS LIBRARY PREP KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY NGS LIBRARY PREP KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY NGS LIBRARY PREP KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY NGS LIBRARY PREP KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROARRAY SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROARRAY SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROARRAY SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROARRAY SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROARRAY SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROARRAY SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY NGS INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY NGS INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY NGS INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY NGS INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY NGS INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY NGS INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INTEGRATION SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INTEGRATION SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INTEGRATION SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INTEGRATION SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INTEGRATION SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INTEGRATION SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MANAGED SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MANAGED SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MANAGED SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MANAGED SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MANAGED SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MANAGED SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CLINICAL LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CLINICAL LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CLINICAL LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CLINICAL LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CLINICAL LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CLINICAL LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY HOSPITAL LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY HOSPITAL LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY HOSPITAL LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY HOSPITAL LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY HOSPITAL LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY HOSPITAL LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROARRAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROARRAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROARRAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROARRAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROARRAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROARRAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY NGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY NGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY NGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY NGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY NGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY NGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION LEVEL, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION LEVEL, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY FULLY AUTOMATED SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY FULLY AUTOMATED SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY FULLY AUTOMATED SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY FULLY AUTOMATED SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY FULLY AUTOMATED SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY FULLY AUTOMATED SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SEMI-AUTOMATED SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SEMI-AUTOMATED SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SEMI-AUTOMATED SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SEMI-AUTOMATED SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SEMI-AUTOMATED SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SEMI-AUTOMATED SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY WALKAWAY AUTOMATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY WALKAWAY AUTOMATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY WALKAWAY AUTOMATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY WALKAWAY AUTOMATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY WALKAWAY AUTOMATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY WALKAWAY AUTOMATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY WOMEN'S HEALTH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY WOMEN'S HEALTH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY WOMEN'S HEALTH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY WOMEN'S HEALTH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY WOMEN'S HEALTH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY WOMEN'S HEALTH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 193. AMERICAS AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 197. AMERICAS AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 198. AMERICAS AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 199. AMERICAS AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2024 (USD MILLION)
  • TABLE 200. AMERICAS AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2025-2032 (USD MILLION)
  • TABLE 201. AMERICAS AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION LEVEL, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION LEVEL, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. NORTH AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 212. NORTH AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 216. NORTH AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2024 (USD MILLION)
  • TABLE 218. NORTH AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2025-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 220. NORTH AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 222. NORTH AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION LEVEL, 2018-2024 (USD MILLION)
  • TABLE 224. NORTH AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION LEVEL, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. LATIN AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 230. LATIN AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 231. LATIN AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 232. LATIN AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 234. LATIN AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2024 (USD MILLION)
  • TABLE 236. LATIN AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2025-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 238. LATIN AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 240. LATIN AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION LEVEL, 2018-2024 (USD MILLION)
  • TABLE 242. LATIN AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION LEVEL, 2025-2032 (USD MILLION)
  • TABLE 243. LATIN AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 244. LATIN AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION LEVEL, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION LEVEL, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE